Kura Oncology (NASDAQ: KURA) grants 185,000 options to CSO

Rhea-AI Filing Summary

Kura Oncology, Inc. reported an equity award to a senior executive. Chief Scientific Officer Francis Burrows received an option to purchase 185,000 shares of Kura Oncology common stock on January 2, 2026 at an exercise price of $10.335 per share. The option was granted as a new award and is held directly.

The option vests in 48 equal monthly installments starting on the grant date, spreading vesting over four years. It is exercisable until January 1, 2036, and covers 185,000 underlying shares of common stock. Following this grant, Burrows beneficially owns 185,000 derivative securities in the form of this stock option.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Burrows Francis

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	185,000	$0.00	--

Holdings After Transaction: Option to purchase common stock — 185,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Francis

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$10.335	01/02/2026		A		185,000		(1)	01/01/2036	Common Stock	185,000	$0	185,000	D

Explanation of Responses:

1. This option vests in 48 equal monthly installments commencing on the grant date.

	Teresa Bair, Attorney-in-fact for Francis Burrows	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) report for Francis Burrows?

Kura Oncology reported that Chief Scientific Officer Francis Burrows received an option to purchase 185,000 shares of common stock on January 2, 2026.

What is the exercise price of the new Kura Oncology (KURA) stock option grant?

The option granted to Chief Scientific Officer Francis Burrows has an exercise price of $10.335 per share of Kura Oncology common stock.

How does the 185,000-share option granted by Kura Oncology (KURA) vest?

The option granted to Francis Burrows vests in 48 equal monthly installments commencing on the January 2, 2026 grant date.

When does the stock option granted to Francis Burrows at Kura Oncology (KURA) expire?

The option to purchase Kura Oncology common stock held by Francis Burrows expires on January 1, 2036.

How many derivative securities does Francis Burrows hold after this Kura Oncology (KURA) grant?

After the reported grant, Francis Burrows beneficially owns 185,000 derivative securities, all in the form of this stock option held directly.

What type of security was granted to the Kura Oncology (KURA) Chief Scientific Officer?

The award is an option to purchase common stock of Kura Oncology, covering 185,000 underlying shares.